Lee S Rosen

Title(s)HS Clinical Professor, Medicine
SchoolMedicine
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments. J Immunother Cancer. 2024 Oct 15; 12(10). Naing A, Khalil D, Rosen O, Camidge DR, Lillie T, Ji RR, Stacey A, Thomas M, Rosen L. PMID: 39414325; PMCID: PMC11481156.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsCTClinical Trials
    2. PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors. ESMO Open. 2024 Sep; 9(9):103653. Yap TA, Choudhury AD, Hamilton E, Rosen LS, Stratton KL, Gordon MS, Schaer D, Liu L, Zhang L, Mittapalli RK, Zhong W, Soman N, Tolcher AW. PMID: 39214047; PMCID: PMC11402040.
      View in: PubMed   Mentions: Translation:HumansAnimalsCTClinical Trials
    3. Correction to: A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies. Invest New Drugs. 2023 Jun; 41(3):539. Khalil DN, González-Albo IP, Rosen L, Lillie T, Stacey A, Parfitt L, Soff GA. PMID: 37166739.
      View in: PubMed   Mentions:    Fields:    
    4. Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced/metastatic epithelial cancer: a phase I clinical trial (SPICE). J Immunother Cancer. 2023 04; 11(4). Fakih M, Harb W, Mahadevan D, Babiker H, Berlin J, Lillie T, Krige D, Carter J, Cox C, Patel M, Parfitt L, Powell M, Rosen L. PMID: 37094988; PMCID: PMC10151977.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCellsCTClinical Trials
    5. A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies. Invest New Drugs. 2023 04; 41(2):317-323. Khalil DN, Prieto González-Albo I, Rosen L, Lillie T, Stacey A, Parfitt L, Soff GA. PMID: 36897458; PMCID: PMC9999314.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    6. Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers. JCO Precis Oncol. 2022 01; 6:e2100418. Drilon A, Tan DSW, Lassen UN, Leyvraz S, Liu Y, Patel JD, Rosen L, Solomon B, Norenberg R, Dima L, Brega N, Shen L, Moreno V, Kummar S, Lin JJ. PMID: 35085007; PMCID: PMC8830513.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    7. Impact of a Palliative Care Nurse Practitioner in an Oncology Clinic: A Quality Improvement Effort. JCO Oncol Pract. 2022 04; 18(4):e484-e494. D'Ambruoso SF, Glaspy JA, Hurvitz SA, Wenger NS, Pietras C, Ahmed K, Drakaki A, Goldman JW, Anand S, Simon W, Kung J, Coscarelli A, Rosen LS, Peddi PF, Wong DJL, Santos K, Phung P, Karlin D, Walling AM. PMID: 34748398.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Therapeutic targeting of SLC6A8 creatine transporter suppresses colon cancer progression and modulates human creatine levels. Sci Adv. 2021 10 08; 7(41):eabi7511. Kurth I, Yamaguchi N, Andreu-Agullo C, Tian HS, Sridhar S, Takeda S, Gonsalves FC, Loo JM, Barlas A, Manova-Todorova K, Busby R, Bendell JC, Strauss J, Fakih M, McRee AJ, Hendifar AE, Rosen LS, Cercek A, Wasserman R, Szarek M, Spector SL, Raza S, Tavazoie MF, Tavazoie SF. PMID: 34613776; PMCID: PMC8494442.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
    9. A Randomized Phase II Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab in Patients with Advanced Gastrointestinal Stromal Tumors. Clin Cancer Res. 2022 01 01; 28(1):84-94. Singh AS, Hecht JR, Rosen L, Wainberg ZA, Wang X, Douek M, Hagopian A, Andes R, Sauer L, Brackert SR, Chow W, DeMatteo R, Eilber FC, Glaspy JA, Chmielowski B. PMID: 34407970.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    10. A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment. Cancer Chemother Pharmacol. 2021 09; 88(3):485-497. Saif MW, Becerra CR, Fakih MG, Sun W, Popovic L, Krishnamurthi S, George TJ, Rudek MA, Shepard DR, Skopek J, Sramek V, Zaric B, Yamamiya I, Benhadji KA, Hamada K, He Y, Rosen L. PMID: 34097100.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    11. Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort. Lung Cancer. 2021 05; 155:151-155. Moreno V, Garrido P, Papadopoulos KP, De Miguel Luken MJ, Gil-Martin M, Aljumaily R, Rosen LS, Rietschel P, Mohan KK, Yoo SY, Stankevich E, Lowy I, Fury MG. PMID: 33831732.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    12. First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies. Clin Cancer Res. 2020 03 01; 26(5):1025-1033. Papadopoulos KP, Johnson ML, Lockhart AC, Moore K, Falchook GS, Formenti SC, Naing A, Carvajal RD, Rosen LS, Weiss GJ, Leidner RS, Li J, Paccaly A, Feng M, Stankevich E, Lowy I, Fury MG, Crittenden MR. PMID: 31796520.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    13. Open-label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment. Br J Clin Pharmacol. 2019 06; 85(6):1239-1246. Saif MW, Rosen L, Rudek MA, Sun W, Shepard DR, Becerra C, Yamashita F, Bebeau P, Winkler R. PMID: 30628113; PMCID: PMC6533429.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    14. A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody-drug conjugate, in patients with breast cancer and other advanced solid tumors. Invest New Drugs. 2020 02; 38(1):120-130. Rosen LS, Wesolowski R, Baffa R, Liao KH, Hua SY, Gibson BL, Pirie-Shepherd S, Tolcher AW. PMID: 30887250.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    15. Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 08; 82(2):339-351. Weekes CD, Rosen LS, Capasso A, Wong KM, Ye W, Anderson M, McCall B, Fredrickson J, Wakshull E, Eppler S, Shon-Nguyen Q, Desai R, Huseni M, Hegde PS, Pourmohamad T, Rhee I, Bessudo A. PMID: 29905898.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    16. Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours. Br J Cancer. 2018 01; 118(2):e3. Infante JR, Korn RL, Rosen LS, LoRusso P, Dychter SS, Zhu J, Maneval DC, Jiang P, Shepard HM, Frost G, Von Hoff DD, Borad MJ, Ramanathan RK. PMID: 29361630; PMCID: PMC5785755.
      View in: PubMed   Mentions: 6     Fields:    
    17. Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer. Invest New Drugs. 2018 08; 36(4):629-637. Goldman JW, Rosen LS, Tolcher AW, Papadopoulos K, Beeram M, Shi P, Pitou C, Bell R, Kulanthaivel P, Zhang X, Fink A, Chan EM, Shahir A, Farrington D, Patnaik A. PMID: 29196957; PMCID: PMC6061137.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    18. Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars. Target Oncol. 2017 Oct; 12(5):599-610. Rosen LS, Jacobs IA, Burkes RL. PMID: 28801849; PMCID: PMC5610666.
      View in: PubMed   Mentions: 76     Fields:    Translation:Humans
    19. Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours. Br J Cancer. 2018 01; 118(2):153-161. Infante JR, Korn RL, Rosen LS, LoRusso P, Dychter SS, Zhu J, Maneval DC, Jiang P, Shepard HM, Frost G, Von Hoff DD, Borad MJ, Ramanathan RK. PMID: 28949957; PMCID: PMC5785735.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCTClinical Trials
    20. A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone. Invest New Drugs. 2017 04; 35(2):189-197. Cleary JM, Rosen LS, Yoshida K, Rasco D, Shapiro GI, Sun W. PMID: 28111727; PMCID: PMC5352756.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    21. Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors. J Clin Oncol. 2016 12 20; 34(36):4371-4380. Leijen S, van Geel RM, Pavlick AC, Tibes R, Rosen L, Razak AR, Lam R, Demuth T, Rose S, Lee MA, Freshwater T, Shumway S, Liang LW, Oza AM, Schellens JH, Shapiro GI. PMID: 27601554; PMCID: PMC7845944.
      View in: PubMed   Mentions: 141     Fields:    Translation:HumansCTClinical Trials
    22. A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer. Clin Cancer Res. 2017 04 15; 23(8):1910-1919. Rosen LS, Goldman JW, Algazi AP, Turner PK, Moser B, Hu T, Wang XA, Tuttle J, Wacheck V, Wooldridge JE, Banck M. PMID: 27803065.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    23. Survival following salvage abdominoperineal resection for persistent and recurrent squamous cell carcinoma of the anus: do these disease categories affect survival? Colorectal Dis. 2016 Oct; 18(10):959-966. Severino NP, Chadi SA, Rosen L, Coiro S, Choman E, Berho M, Wexner SD. PMID: 26850085.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    24. A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors. Invest New Drugs. 2016 10; 34(5):604-13. Rosen LS, LoRusso P, Ma WW, Goldman JW, Weise A, Colevas AD, Adjei A, Yazji S, Shen A, Johnston S, Hsieh HJ, Chan IT, Sikic BI. PMID: 27424159; PMCID: PMC6863157.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCTClinical Trials
    25. Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors. Cancer Discov. 2016 07; 6(7):740-53. Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, Papadopoulos KP, Beeram M, Rasco DW, Hilton JF, Nasir A, Beckmann RP, Schade AE, Fulford AD, Nguyen TS, Martinez R, Kulanthaivel P, Li LQ, Frenzel M, Cronier DM, Chan EM, Flaherty KT, Wen PY, Shapiro GI. PMID: 27217383.
      View in: PubMed   Mentions: 336     Fields:    Translation:HumansAnimals
    26. Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors. Drugs R D. 2016 Mar; 16(1):45-52. Falchook GS, Zhou X, Venkatakrishnan K, Kurzrock R, Mahalingam D, Goldman JW, Jung J, Ullmann CD, Milch C, Rosen LS, Sarantopoulos J. PMID: 26689566; PMCID: PMC4767718.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    27. Clinical translation of ferumoxytol-based vessel size imaging (VSI): Feasibility in a phase I oncology clinical trial population. Magn Reson Med. 2017 02; 77(2):814-825. Fredrickson J, Serkova NJ, Wyatt SK, Carano RA, Pirzkall A, Rhee I, Rosen LS, Bessudo A, Weekes C, de Crespigny A. PMID: 26918893; PMCID: PMC5677523.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCTClinical Trials
    28. Erratum to: Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer. Cancer Chemother Pharmacol. 2016 Feb; 77(2):439. Bendell JC, Rosen LS, Mayer RJ, Goldman JW, Infante JR, Benedetti F, Lin D, Mizuguchi H, Zergebel C, Patel MR. PMID: 26589791; PMCID: PMC4969883.
      View in: PubMed   Mentions:    Fields:    
    29. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study. Cancer Chemother Pharmacol. 2015 Nov; 76(5):1041-9. Tolcher AW, LoRusso P, Arzt J, Busman TA, Lian G, Rudersdorf NS, Vanderwal CA, Waring JF, Yang J, Holen KD, Rosen LS. PMID: 26429709.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    30. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2015 Nov; 76(5):1025-32. Tolcher AW, LoRusso P, Arzt J, Busman TA, Lian G, Rudersdorf NS, Vanderwal CA, Kirschbrown W, Holen KD, Rosen LS. PMID: 26420235.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    31. Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer. Cancer Chemother Pharmacol. 2015 Nov; 76(5):925-32. Bendell JC, Rosen LS, Mayer RJ, Goldman JW, Infante JR, Benedetti F, Lin D, Mizuguchi H, Zergebel C, Patel MR. PMID: 26370544; PMCID: PMC4612319.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    32. Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors. Int J Clin Pharmacol Ther. 2015 Jul; 53(7):563-72. Falchook GS, Venkatakrishnan K, Sarantopoulos J, Kurzrock R, Mita AC, Fu S, Mita MM, Zhou X, Jung JA, Ullmann CD, Milch C, Rosen LS. PMID: 26073352.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    33. Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. J Clin Oncol. 2015 Mar 20; 33(9):1060-6. Daud AI, Ashworth MT, Strosberg J, Goldman JW, Mendelson D, Springett G, Venook AP, Loechner S, Rosen LS, Shanahan F, Parry D, Shumway S, Grabowsky JA, Freshwater T, Sorge C, Kang SP, Isaacs R, Munster PN. PMID: 25605849.
      View in: PubMed   Mentions: 100     Fields:    Translation:HumansCellsCTClinical Trials
    34. Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib. Cancer. 2015 05 01; 121(9):1405-13. Reichardt P, Kang YK, Rutkowski P, Schuette J, Rosen LS, Seddon B, Yalcin S, Gelderblom H, Williams CC, Fumagalli E, Biasco G, Hurwitz HI, Kaiser PE, Fly K, Matczak E, Chen L, Lechuga MJ, Demetri GD. PMID: 25641662; PMCID: PMC4442000.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCTClinical Trials
    35. Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors. Clin Cancer Res. 2015 Mar 01; 21(5):1002-9. Goldman J, Eckhardt SG, Borad MJ, Curtis KK, Hidalgo M, Calvo E, Ryan DP, Wirth LJ, Parikh A, Partyka J, Faessel H, Gangolli E, Stewart S, Rosen LS, Bowles DW. PMID: 25501576.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCellsCTClinical Trials
    36. A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours. Oncotarget. 2014 Nov 30; 5(22):11154-67. Hong DS, Kurzrock R, Mulay M, Rasmussen E, Wu BM, Bass MB, Zhong ZD, Friberg G, Rosen LS. PMID: 25525888; PMCID: PMC4294348.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    37. An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer. Clin Cancer Res. 2014 Dec 01; 20(23):5918-26. Gordon MS, Robert F, Matei D, Mendelson DS, Goldman JW, Chiorean EG, Strother RM, Seon BK, Figg WD, Peer CJ, Alvarez D, Adams BJ, Theuer CP, Rosen LS. PMID: 25261556; PMCID: PMC4570619.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCTClinical Trials
    38. A phase 1 study to evaluate effect of food on veliparib pharmacokinetics and relative bioavailability in subjects with solid tumors. Cancer Chemother Pharmacol. 2014 Sep; 74(3):583-91. Mostafa NM, Chiu YL, Rosen LS, Bessudo A, Kovacs X, Giranda VL. PMID: 25053388.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    39. Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-XL , in patients with cancer. J Clin Pharm Ther. 2014 Dec; 39(6):680-4. Yang J, Pradhan RS, Rosen LS, Graham AM, Holen KD, Xiong H. PMID: 25047139.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    40. Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul; 74(1):195-204. Mita M, Gordon M, Rosen L, Kapoor N, Choy G, Redkar S, Taverna P, Oganesian A, Sahai A, Azab M, Bristow R, Tolcher AW. PMID: 24849582.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCellsCTClinical Trials
    41. Extended progression-free survival in two patients with alveolar soft part sarcoma exposed to tivantinib. J Clin Oncol. 2014 Dec 01; 32(34):e114-6. Goldberg JM, Gavcovich T, Saigal G, Goldman JW, Rosen LS. PMID: 24550414; PMCID: PMC4876351.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    42. Endoglin for targeted cancer treatment. Curr Oncol Rep. 2014 Feb; 16(2):365. Rosen LS, Gordon MS, Robert F, Matei DE. PMID: 24445497.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    43. A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours. Eur J Cancer. 2014 Mar; 50(5):867-75. Tolcher A, Goldman J, Patnaik A, Papadopoulos KP, Westwood P, Kelly CS, Bumgardner W, Sams L, Geeganage S, Wang T, Capen AR, Huang J, Joseph S, Miller J, Benhadji KA, Brail LH, Rosen LS. PMID: 24440085.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCellsCTClinical Trials
    44. A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas. Clin Cancer Res. 2013 Nov 01; 19(21):6020-9. Wagner AJ, Chugh R, Rosen LS, Morgan JA, George S, Gordon M, Dunbar J, Normant E, Grayzel D, Demetri GD. PMID: 24045182; PMCID: PMC4330562.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCTClinical Trials
    45. Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors. Clin Cancer Res. 2013 Sep 01; 19(17):4824-31. Hong D, Said R, Falchook G, Naing A, Moulder S, Tsimberidou AM, Galluppi G, Dakappagari N, Storgard C, Kurzrock R, Rosen LS. PMID: 23873691; PMCID: PMC3935614.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    46. The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors. BMC Cancer. 2013 May 16; 13:242. Rosen LS, Lipton L, Price TJ, Belman ND, Boccia RV, Hurwitz HI, Stephenson JJ, Wirth LJ, McCoy S, Hei YJ, Hsu CP, Tebbutt NC. PMID: 23679351; PMCID: PMC3688238.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    47. A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies. BMC Cancer. 2013 Mar 25; 13:152. Goldman JW, Raju RN, Gordon GA, El-Hariry I, Teofilivici F, Vukovic VM, Bradley R, Karol MD, Chen Y, Guo W, Inoue T, Rosen LS. PMID: 23530663; PMCID: PMC3626541.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCTClinical Trials
    48. A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors. Clin Cancer Res. 2013 Jan 01; 19(1):268-78. Jameson GS, Hamm JT, Weiss GJ, Alemany C, Anthony S, Basche M, Ramanathan RK, Borad MJ, Tibes R, Cohn A, Hinshaw I, Jotte R, Rosen LS, Hoch U, Eldon MA, Medve R, Schroeder K, White E, Von Hoff DD. PMID: 23136196; PMCID: PMC4104496.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    49. A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors. Invest New Drugs. 2013 Jun; 31(3):714-23. Gordon MS, Rosen LS, Mendelson D, Ramanathan RK, Goldman J, Liu L, Xu Y, Gerson SL, Anthony SP, Figg WD, Spencer S, Adams BJ, Theuer CP, Leigh BR, Weiss GJ. PMID: 23054206; PMCID: PMC6662598.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCellsCTClinical Trials
    50. A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors. Clin Cancer Res. 2012 Sep 15; 18(18):5090-8. Jhaveri K, Miller K, Rosen L, Schneider B, Chap L, Hannah A, Zhong Z, Ma W, Hudis C, Modi S. PMID: 22781552.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    51. A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. Clin Cancer Res. 2012 Sep 01; 18(17):4820-9. Rosen LS, Hurwitz HI, Wong MK, Goldman J, Mendelson DS, Figg WD, Spencer S, Adams BJ, Alvarez D, Seon BK, Theuer CP, Leigh BR, Gordon MS. PMID: 22767667; PMCID: PMC3432706.
      View in: PubMed   Mentions: 111     Fields:    Translation:HumansCTClinical Trials
    52. Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib. Cancer. 2012 Dec 01; 118(23):5903-11. Goldman JW, Laux I, Chai F, Savage RE, Ferrari D, Garmey EG, Just RG, Rosen LS. PMID: 22605616.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCTClinical Trials
    53. Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. Cancer. 2012 Dec 01; 118(23):5894-902. Wagner AJ, Goldberg JM, Dubois SG, Choy E, Rosen L, Pappo A, Geller J, Judson I, Hogg D, Senzer N, Davis IJ, Chai F, Waghorne C, Schwartz B, Demetri GD. PMID: 22605650.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansCTClinical Trials
    54. Unexpected renal toxicity associated with SGX523, a small molecule inhibitor of MET. Invest New Drugs. 2013 Apr; 31(2):363-9. Infante JR, Rugg T, Gordon M, Rooney I, Rosen L, Zeh K, Liu R, Burris HA, Ramanathan RK. PMID: 22547164.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCTClinical Trials
    55. Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors. Clin Cancer Res. 2012 Jun 15; 18(12):3414-27. Rosen LS, Puzanov I, Friberg G, Chan E, Hwang YC, Deng H, Gilbert J, Mahalingam D, McCaffery I, Michael SA, Mita AC, Mita MM, Mulay M, Shubhakar P, Zhu M, Sarantopoulos J. PMID: 22510349.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    56. A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer. Cancer Invest. 2011 Nov; 29(9):617-25. Wong NS, Meadows KL, Rosen LS, Adjei AA, Kaufmann SH, Morse MA, Petros WP, Zhu Y, Statkevich P, Cutler DL, Meyers ML, Hurwitz HI. PMID: 22011284; PMCID: PMC4101887.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    57. Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res. 2011 Nov 01; 17(21):6888-96. Gerber DE, Stopeck AT, Wong L, Rosen LS, Thorpe PE, Shan JS, Ibrahim NK. PMID: 21989064.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCellsCTClinical Trials
    58. A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Clin Cancer Res. 2011 Dec 15; 17(24):7754-64. Rosen LS, Senzer N, Mekhail T, Ganapathi R, Chai F, Savage RE, Waghorne C, Abbadessa G, Schwartz B, Dreicer R. PMID: 21976535.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCTClinical Trials
    59. An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function. Cancer Chemother Pharmacol. 2012 Mar; 69(3):605-12. O'Bryant CL, Haluska P, Rosen L, Ramanathan RK, Venugopal B, Leong S, Boinpally R, Franke A, Witt K, Evans J, Belani C, Gail Eckhardt S, Ramalingam S. PMID: 21938545.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCellsCTClinical Trials
    60. A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics of 5-fluorouracil. Anticancer Res. 2011 Feb; 31(2):625-32. Saif MW, Rosen LS, Saito K, Zergebel C, Ravage-Mass L, Mendelson DS. PMID: 21378348.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    61. Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients. Cancer Sci. 2011 Feb; 102(2):478-83. Chuah B, Goh BC, Lee SC, Soong R, Lau F, Mulay M, Dinolfo M, Lim SE, Soo R, Furuie T, Saito K, Zergebel C, Rosen LS. PMID: 21143703.
      View in: PubMed   Mentions: 56     Fields:    Translation:Humans
    62. A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. Ann Oncol. 2011 Jun; 22(6):1413-1419. Jonker DJ, Rosen LS, Sawyer MB, de Braud F, Wilding G, Sweeney CJ, Jayson GC, McArthur GA, Rustin G, Goss G, Kantor J, Velasquez L, Syed S, Mokliatchouk O, Feltquate DM, Kollia G, Nuyten DSA, Galbraith S. PMID: 21131369; PMCID: PMC3139984.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    63. Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors. Cancer Chemother Pharmacol. 2011 Jul; 68(1):69-77. Benjamin RS, Schöffski P, Hartmann JT, Van Oosterom A, Bui BN, Duyster J, Schuetze S, Blay JY, Reichardt P, Rosen LS, Skubitz K, McCoy S, Sun YN, Stepan DE, Baker L. PMID: 20838998; PMCID: PMC3123696.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    64. Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer. 2010 Mar 15; 116(6):1582-91. Johnson FM, Agrawal S, Burris H, Rosen L, Dhillon N, Hong D, Blackwood-Chirchir A, Luo FR, Sy O, Kaul S, Chiappori AA. PMID: 20108303.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCTClinical Trials
    65. Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review. Oncologist. 2010; 15(3):216-35. Rosen LS, Ashurst HL, Chap L. PMID: 20200040; PMCID: PMC3227950.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    66. Phase 1 experience with an anti-glycotope monoclonal antibody, RAV12, in recurrent adenocarcinoma. Clin Cancer Res. 2010 Mar 01; 16(5):1673-81. Burris HA, Rosen LS, Rocha-Lima CM, Marshall J, Jones S, Cohen RB, Kunkel LA, Loo D, Baughman J, Stewart SJ, Lewis N. PMID: 20179219.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    67. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol. 2010 Jul; 66(2):357-71. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ. PMID: 19967539.
      View in: PubMed   Mentions: 185     Fields:    Translation:HumansCells
    68. Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib. Clin Cancer Res. 2009 Nov 15; 15(22):7045-52. Bello CL, Mulay M, Huang X, Patyna S, Dinolfo M, Levine S, Van Vugt A, Toh M, Baum C, Rosen L. PMID: 19903787.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    69. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol. 2009 Jul 20; 27(21):3557-65. Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, Rasmussen E, Sun YN, Zhong D, Hwang YC, Evelhoch JL, Oliner JD, Le N, Rosen LS. PMID: 19546406.
      View in: PubMed   Mentions: 89     Fields:    Translation:HumansCTClinical Trials
    70. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res. 2009 Jun 15; 15(12):4213-9. Tan AR, Rubin EH, Walton DC, Shuster DE, Wong YN, Fang F, Ashworth S, Rosen LS. PMID: 19509146.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCTClinical Trials
    71. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008 Oct 10; 26(29):4708-13. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB. PMID: 18541897; PMCID: PMC4859206.
      View in: PubMed   Mentions: 233     Fields:    Translation:HumansCTClinical Trials
    72. Role of palifermin in fluorouracil-based therapy for metastatic colorectal cancer. J Clin Oncol. 2008 Mar 10; 26(8):1386-7. Zalcberg JR, Rosen LS, Abdi E, Davis ID, Gutheil J, Schnell FM, Cesano A, Gayko U, Chen MG, Clarke S. PMID: 18323563.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    73. Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma. Clin Colorectal Cancer. 2008 Jan; 7(1):44-7. Berlin JD, Venook A, Bergsland E, Rothenberg M, Lockhart AC, Rosen L. PMID: 18279576.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    74. New approaches to assessing and treating early-stage colon and rectal cancer: summary statement from 2007 Santa Monica Conference. Clin Cancer Res. 2007 Nov 15; 13(22 Pt 2):6853s-6s. Rosen LS, Bilchik AJ, Beart RW, Benson AB, Chang KJ, Compton CC, Grothey A, Haller DG, Ko CY, Lynch PM, Nelson H, Stamos MJ, Turner RR, Willett CG. PMID: 18006789.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    75. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol. 2007 Oct 20; 25(30):4793-9. Saltz LB, Rosen LS, Marshall JL, Belt RJ, Hurwitz HI, Eckhardt SG, Bergsland EK, Haller DG, Lockhart AC, Rocha Lima CM, Huang X, DePrimo SE, Chow-Maneval E, Chao RC, Lenz HJ. PMID: 17947727.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCTClinical Trials
    76. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2007 Jun 10; 25(17):2369-76. Rosen LS, Kurzrock R, Mulay M, Van Vugt A, Purdom M, Ng C, Silverman J, Koutsoukos A, Sun YN, Bass MB, Xu RY, Polverino A, Wiezorek JS, Chang DD, Benjamin R, Herbst RS. PMID: 17557949.
      View in: PubMed   Mentions: 67     Fields:    Translation:HumansCTClinical Trials
    77. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid. 2007 Apr; 17(4):351-5. Wong E, Rosen LS, Mulay M, Vanvugt A, Dinolfo M, Tomoda C, Sugawara M, Hershman JM. PMID: 17465866.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    78. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol. 2006 Nov 20; 24(33):5194-200. Rosen LS, Abdi E, Davis ID, Gutheil J, Schnell FM, Zalcberg J, Cesano A, Gayko U, Chen MG, Clarke S. PMID: 17075109.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    79. Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma. Invest New Drugs. 2007 Feb; 25(1):85-94. Jhawer M, Rosen L, Dancey J, Hochster H, Hamburg S, Tempero M, Clendeninn N, Mani S. PMID: 16957834.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    80. Overview of anti-VEGF therapy and angiogenesis. Part 1: Angiogenesis inhibition in solid tumor malignancies. Clin Adv Hematol Oncol. 2006 Jan; 4(1):suppl 1-10; quz 11-2. Ellis LM, Rosen L, Gordon MS. PMID: 16562372.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    81. Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J Clin Oncol. 2005 Dec 20; 23(36):9073-8. Bilchik AJ, Poston G, Curley SA, Strasberg S, Saltz L, Adam R, Nordlinger B, Rougier P, Rosen LS. PMID: 16361615.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    82. VEGF-targeted therapy: therapeutic potential and recent advances. Oncologist. 2005 Jun-Jul; 10(6):382-91. Rosen LS. PMID: 15967832.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    83. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. Clin Lung Cancer. 2004 Nov; 6(3):170-4. Hirsh V, Tchekmedyian NS, Rosen LS, Zheng M, Hei YJ. PMID: 15555218.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    84. Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 2):6397S-403S. Lipton A, Colombo-Berra A, Bukowski RM, Rosen L, Zheng M, Urbanowitz G. PMID: 15448038.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCTClinical Trials
    85. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer. 2004 Jun 15; 100(12):2613-21. Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J. PMID: 15197804.
      View in: PubMed   Mentions: 185     Fields:    Translation:HumansCTClinical Trials
    86. Phase 1 study of TLK286 (Telcyta) administered weekly in advanced malignancies. Clin Cancer Res. 2004 Jun 01; 10(11):3689-98. Rosen LS, Laxa B, Boulos L, Wiggins L, Keck JG, Jameson AJ, Parra R, Patel K, Brown GL. PMID: 15173075.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    87. New generation of bisphosphonates: broad clinical utility in breast and prostate cancer. Oncology (Williston Park). 2004 May; 18(5 Suppl 3):26-32. Rosen LS. PMID: 15202585.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    88. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer. 2004 Jan 01; 100(1):36-43. Rosen LS, Gordon DH, Dugan W, Major P, Eisenberg PD, Provencher L, Kaminski M, Simeone J, Seaman J, Chen BL, Coleman RE. PMID: 14692022.
      View in: PubMed   Mentions: 81     Fields:    Translation:HumansCTClinical Trials
    89. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003 Oct 15; 98(8):1735-44. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen BL, Seaman JJ. PMID: 14534891.
      View in: PubMed   Mentions: 215     Fields:    Translation:HumansCTClinical Trials
    90. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003 Aug 15; 21(16):3150-7. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman JJ. PMID: 12915606.
      View in: PubMed   Mentions: 209     Fields:    Translation:HumansCTClinical Trials
    91. Phase I study of TLK286 (glutathione S-transferase P1-1 activated glutathione analogue) in advanced refractory solid malignancies. Clin Cancer Res. 2003 May; 9(5):1628-38. Rosen LS, Brown J, Laxa B, Boulos L, Reiswig L, Henner WD, Lum RT, Schow SR, Maack CA, Keck JG, Mascavage JC, Dombroski JA, Gomez RF, Brown GL. PMID: 12738715.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    92. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol. 2003 Apr 15; 21(8):1452-8. Meropol NJ, Somer RA, Gutheil J, Pelley RJ, Modiano MR, Rowinsky EK, Rothenberg ML, Redding SW, Serdar CM, Yao B, Heard R, Rosen LS. PMID: 12697866.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    93. Broad clinical activity of zoledronic acid in osteolytic to osteoblastic bone lesions in patients with a broad range of solid tumors. Am J Clin Oncol. 2002 Dec; 25(6 Suppl 1):S19-24. Rosen L, Harland SJ, Oosterlinck W. PMID: 12562047.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    94. Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors. Semin Oncol. 2002 Dec; 29(6 Suppl 21):28-32. Rosen LS. PMID: 12584692.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    95. Inhibitors of the vascular endothelial growth factor receptor. Hematol Oncol Clin North Am. 2002 Oct; 16(5):1173-87. Rosen LS. PMID: 12512388.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimals
    96. Biologic approaches to the treatment of gastrointestinal malignancy. Curr Opin Oncol. 2002 Jul; 14(4):431-8. Rosen LS. PMID: 12130929.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    97. Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma. Cancer. 2002 Apr 15; 94(8):2174-9. Delioukina ML, Prager D, Parson M, Hecht JR, Rosen P, Rosen LS. PMID: 12001114.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    98. Low-dose trimetrexate glucuronate and protracted 5-fluorouracil infusion in previously untreated patients with advanced pancreatic cancer. Ann Oncol. 2002 Apr; 13(4):582-8. Amado RG, Rosen LS, Hecht JR, Lin LS, Rosen PJ. PMID: 12056709.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    99. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol. 2002 Mar 15; 20(6):1657-67. Kuenen BC, Rosen L, Smit EF, Parson MR, Levi M, Ruijter R, Huisman H, Kedde MA, Noordhuis P, van der Vijgh WJ, Peters GJ, Cropp GF, Scigalla P, Hoekman K, Pinedo HM, Giaccone G. PMID: 11896117.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
    100. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control. 2002 Mar-Apr; 9(2 Suppl):36-44. Rosen LS. PMID: 11965229.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansAnimals
    101. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest. 2002; 20 Suppl 2:45-54. Lipton A, Small E, Saad F, Gleason D, Gordon D, Smith M, Rosen L, Kowalski MO, Reitsma D, Seaman J. PMID: 12442349.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCells
    102. Angiogenesis inhibition in solid tumors. Cancer J. 2001 Nov-Dec; 7 Suppl 3:S120-8. Rosen LS. PMID: 11779082.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    103. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001 Sep-Oct; 7(5):377-87. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y. PMID: 11693896.
      View in: PubMed   Mentions: 197     Fields:    Translation:HumansCTClinical Trials
    104. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer. 2001 Apr 01; 91(7):1191-200. Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, Dreicer R, Kuross SA, Lipton A, Seaman JJ. PMID: 11283917.
      View in: PubMed   Mentions: 101     Fields:    Translation:HumansCTClinical Trials
    105. A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. Clin Cancer Res. 2001 Mar; 7(3):478-85. Berenson JR, Vescio RA, Rosen LS, VonTeichert JM, Woo M, Swift R, Savage A, Givant E, Hupkes M, Harvey H, Lipton A. PMID: 11297237.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    106. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000 Sep 28; 343(13):905-14. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL. PMID: 11006366.
      View in: PubMed   Mentions: 711     Fields:    Translation:HumansCTClinical Trials
    107. Antiangiogenic strategies and agents in clinical trials. Oncologist. 2000; 5 Suppl 1:20-7. Rosen L. PMID: 10804087.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    108. Irinotecan in lymphoma, leukemia, and breast, pancreatic, ovarian, and small-cell lung cancers. Oncology (Williston Park). 1998 Aug; 12(8 Suppl 6):103-9. Rosen LS. PMID: 9726101.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimals
    109. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg. 1998 Jul; 187(1):69-77; discussion 77-9. Wallack MK, Sivanandham M, Balch CM, Urist MM, Bland KI, Murray D, Robinson WA, Flaherty L, Richards JM, Bartolucci AA, Rosen L. PMID: 9660028.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCellsCTClinical Trials
    110. Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. J Clin Pharmacol. 1997 Apr; 37(4):285-90. Berenson JR, Rosen L, Vescio R, Lau HS, Woo M, Sioufi A, Kowalski MO, Knight RD, Seaman JJ. PMID: 9115053.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    111. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology. 1997 Feb; 112(2):594-642. Winawer SJ, Fletcher RH, Miller L, Godlee F, Stolar MH, Mulrow CD, Woolf SH, Glick SN, Ganiats TG, Bond JH, Rosen L, Zapka JG, Olsen SJ, Giardiello FM, Sisk JE, Van Antwerp R, Brown-Davis C, Marciniak DA, Mayer RJ. PMID: 9024315.
      View in: PubMed   Mentions: 337     Fields:    Translation:HumansPHPublic Health
    112. Adapting a statewide patient database for comparative analysis and quality improvement. Jt Comm J Qual Improv. 1996 Jul; 22(7):468-81. Rosen LS, Schroeder K, Hagan M, Acord-Szczesny J, Garavaglia M. PMID: 8858418.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    113. Production of anti-erythrocyte antibodies by leukemic and nonleukemic B cells in chronic lymphocytic leukemia patients. Leuk Lymphoma. 1996 Feb; 20(5-6):465-69. Centola M, Lin K, Sutton C, Berenson JR, Kunkel LA, Rosen L, Hahn BH, Robinson RR. PMID: 8833404.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    114. Deletion of genetic material from a poly(ADP-ribose) polymerase-like gene on chromosome 13 occurs frequently in patients with monoclonal gammopathies. Cancer Epidemiol Biomarkers Prev. 1995 Oct-Nov; 4(7):759-63. Cao J, Hong CH, Rosen L, Vescio RA, Smulson M, Lichtenstein AK, Berenson JR. PMID: 8672993.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    115. Comparing predictive decision rules in postoperative CEA monitoring. Cancer. 1986 Nov 01; 58(9):2089-95. Denstman F, Rosen L, Khubchandani IT, Sheets JA, Stasik JJ, Riether RD. PMID: 3756825.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    Lee's Networks
    Concepts (444)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (35)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California